That means you can have reports backed by clinical diagnosis, as well as subjective reports where there is no clinician-confirmed diagnosis of hair loss
Preliminary human studies suggest a favorable safety profile, though clinical efficacy data remain limited
Nevertheless, according to the European Medicines Agencys (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) findings from October 2023, there is no evidence to suggest a causal relationship between GLP-1 receptor agonists (including exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide) and thyroid cancer [56]
The biological actions of GLP-1 across a wide range of tissues, including the pancreas, brain, cardiovascular system, and liver, are mediated through the GLP-1R, a class B1 G protein-coupled receptor (GPCR) (Zheng et al., 2024)
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Organ Damage: A Current Perspective
If more Medicare beneficiaries with obesity or overweight gain access to GLP-1s based on other approved uses for these medications, that could reduce the cost of proposed legislation to lift the statutory prohibition on Medicare coverage of anti-obesity drugs
